QUOTE AND NEWS
TheStreet.com  Jul 16  Comment 
NEW YORK (TheStreet) -- Sanofi reportedly held talks with Abbott Laboratories , Mylan  and private equity firms over the possible sale of a $8.5 billion portfolio of mature drugs, according to an internal document seen by Reuters. The 25-page...
FiercePharma  Jul 16  Comment 
The pharma sector in India is reeling after the National Pharmaceutical Pricing Authority said it's capping prices on about 100 drugs to treat diabetes and heart disease. And the company that could suffer most isn't India-based.
The Economic Times  Jul 14  Comment 
Sanofi India's stock tanked 10.22 per cent to settle at Rs 2,900. In intra-day trade, the scrip plunged 10.99 per cent to Rs 2,875.
Motley Fool  Jul 13  Comment 
And how a company can do well by doing good.
FierceBiotech  Jul 11  Comment 
Capping a 20-year effort to develop the world's first dengue fever vaccine, Sanofi has come through with positive results from a sweeping Phase III trial, but its candidate is not quite a panacea for the often deadly disease.
Benzinga  Jul 11  Comment 
Below are the top drug manufacturers-major stocks on the NYSE in terms of dividend yield. AstraZeneca PLC (NYSE: AZN) has a dividend yield of 5.00%. AstraZeneca's shares closed at $74.72 on Thursday. GlaxoSmithKline plc (NYSE: GSK) has a...
Motley Fool  Jul 10  Comment 
Read below for more on this exciting story.
Wall Street Journal  Jul 9  Comment 
Regeneron Pharmaceuticals and Sanofi said they would begin a late-stage study of an experimental treatment for chronic eczema in hopes of gaining U.S. regulatory approval.
MedPage Today  Jul 9  Comment 
(MedPage Today) -- The FDA has accepted Sanofi's new drug application for an upgraded formulation of its insulin glargine (Lantus), which is set to come off patent next year.
FiercePharma  Jul 9  Comment 
Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until at least mid-2016. But now, it's filed another, wider suit.




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki